Open AccessThe pathological consequences of anaemia
Author(s) -
Silverberg D.S.,
Iaina A.,
Wexler D.,
Blum M.
Publication year - 2001
Publication title -
clinical & laboratory haematology
Language(s) - English
Resource type - Journals
eISSN - 1365-2257
pISSN - 0141-9854
DOI - 10.1046/j.1365-2257.2001.00352.x
Subject(s) - medicine , erythropoietin , cachexia , anemia , heart failure , weakness , iron deficiency , rheumatoid arthritis , pathological , bone marrow , intensive care medicine , surgery , cancer
Many patients with chronic diseases such as chronic renal failure, chronic inflammatory bowel disease and rheumatoid arthritis are anaemic. Recently congestive heart failure (CHF) has also been found to be associated with anaemia. In all these diseases this anaemia or chronic disease is at least partially due to excessive production of cytokines and leukotrines that interfere both with the effect of erythropoietin (EPO) at the bone marrow and the release of stored iron in the reticuloendothelial system. Treating this anaemia with subcutaneous EPO and IV iron improves the weakness, fatigue, cachexia, nutritional state, mood, cognitive function and quality of life. In the case of CHF it also improves cardiac function and patient functional class, prevents deterioration of renal function and markedly reduces hospitalization. Very few agents in medicine improve so many aspects of the patient so well and so quickly. Unfortunately (for the suffering patient) this anaemia is often ignored and goes untreated.